$BCRX
BIOCRYST PHARMACEUTICALS INC

2024 Q4 Form 10-Q Financial Statement

#000162828024045364 Filed on November 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $117.1M
YoY Change 34.98%
Cost Of Revenue $3.211M
YoY Change 192.17%
Gross Profit $113.9M
YoY Change 32.96%
Gross Profit Margin 97.26%
Selling, General & Admin $65.08M
YoY Change 28.5%
% of Gross Profit 57.15%
Research & Development $41.08M
YoY Change -12.37%
% of Gross Profit 36.08%
Depreciation & Amortization $311.0K
YoY Change -25.95%
% of Gross Profit 0.27%
Operating Expenses $106.2M
YoY Change 8.86%
Operating Profit $7.692M
YoY Change -164.52%
Interest Expense -$21.14M
YoY Change -177.3%
% of Operating Profit -274.82%
Other Income/Expense, Net
YoY Change
Pretax Income -$13.45M
YoY Change -62.46%
Income Tax $586.0K
% Of Pretax Income
Net Earnings -$14.03M
YoY Change -61.18%
Net Earnings / Revenue -11.99%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.07
COMMON SHARES
Basic Shares Outstanding 207.1M shares 206.9M shares
Diluted Shares Outstanding 206.9M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $330.0M
YoY Change -17.0%
Cash & Equivalents $96.84M
Short-Term Investments $233.2M
Other Short-Term Assets $17.09M
YoY Change -20.86%
Inventory $7.562M
Prepaid Expenses
Receivables $72.46M
Other Receivables $0.00
Total Short-Term Assets $427.1M
YoY Change -14.99%
LONG-TERM ASSETS
Property, Plant & Equipment $7.421M
YoY Change -17.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.43M
YoY Change
Other Assets $15.65M
YoY Change 36.57%
Total Long-Term Assets $64.13M
YoY Change 213.47%
TOTAL ASSETS
Total Short-Term Assets $427.1M
Total Long-Term Assets $64.13M
Total Assets $491.3M
YoY Change -6.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.48M
YoY Change 27.59%
Accrued Expenses $104.2M
YoY Change 34.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $34.84M
YoY Change
Total Short-Term Liabilities $153.6M
YoY Change 69.2%
LONG-TERM LIABILITIES
Long-Term Debt $314.3M
YoY Change 5.48%
Other Long-Term Liabilities $8.065M
YoY Change -19.35%
Total Long-Term Liabilities $314.3M
YoY Change 5.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $153.6M
Total Long-Term Liabilities $314.3M
Total Liabilities $959.8M
YoY Change 146.89%
SHAREHOLDERS EQUITY
Retained Earnings -$1.743B
YoY Change 7.65%
Common Stock $2.071M
YoY Change 9.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$468.6M
YoY Change
Total Liabilities & Shareholders Equity $491.3M
YoY Change -6.06%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$14.03M
YoY Change -61.18%
Depreciation, Depletion And Amortization $311.0K
YoY Change -25.95%
Cash From Operating Activities $8.245M
YoY Change -141.45%
INVESTING ACTIVITIES
Capital Expenditures $59.00K
YoY Change -93.98%
Acquisitions
YoY Change
Other Investing Activities $8.548M
YoY Change -64.55%
Cash From Investing Activities $8.489M
YoY Change -63.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.274M
YoY Change 3.58%
NET CHANGE
Cash From Operating Activities 8.245M
Cash From Investing Activities 8.489M
Cash From Financing Activities 1.274M
Net Change In Cash 18.01M
YoY Change 304.67%
FREE CASH FLOW
Cash From Operating Activities $8.245M
Capital Expenditures $59.00K
Free Cash Flow $8.186M
YoY Change -139.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01
dei Trading Symbol
TradingSymbol
BCRX
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
207132571 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96841000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110643000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
813000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1804000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
233172000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
72456000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56950000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
7562000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
28683000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16281000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19542000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
427125000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
495966000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1049000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1058000 usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35379000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
552000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
238011000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
109393000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-811000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46807000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86223000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1614000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
12000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-468563000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0000882796
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
BIOCRYST PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
62-1413174
dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Address Address Line1
EntityAddressAddressLine1
4505 Emperor Blvd., Suite 200
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
21633000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7421000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7910000 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
19426000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
0 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15649000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13084000 usd
CY2024Q3 us-gaap Assets
Assets
491254000 usd
CY2023Q4 us-gaap Assets
Assets
516960000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
20893000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
104197000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
102882000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1839000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1590000 usd
CY2024Q3 bcrx Royalty Financing Liabilities Current
RoyaltyFinancingLiabilitiesCurrent
33000000 usd
CY2023Q4 bcrx Royalty Financing Liabilities Current
RoyaltyFinancingLiabilitiesCurrent
23565000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
153567000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
149988000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8065000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8390000 usd
CY2024Q3 bcrx Royalty Financing Liabilities Noncurrent
RoyaltyFinancingLiabilitiesNoncurrent
481775000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
314333000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
303231000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
17000 usd
CY2023Q3 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
37000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
98663000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7692000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11921000 usd
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
3591000 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
4184000 usd
CY2024Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
98000 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13447000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35819000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
586000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
330000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14033000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36149000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
563000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-185000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1173000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
295000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12297000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
206905000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
206905000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189644000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189644000 shares
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
306239000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
dei Entity File Number
EntityFileNumber
000-23186
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27703
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
859-1302
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
278344000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13482000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2077000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2845000 usd
CY2023Q4 bcrx Royalty Financing Liabilities Noncurrent
RoyaltyFinancingLiabilitiesNoncurrent
508034000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
959817000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
972488000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
207119000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
207119000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
205771000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
205771000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2071000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2058000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1270318000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1222236000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2293000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1337000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1743245000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1681159000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-468563000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-455528000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
491254000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
516960000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
117085000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
319178000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3211000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1099000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6175000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2924000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41081000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46879000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125197000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146514000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
65084000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50648000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
185662000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149512000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
179000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
100000 usd
us-gaap Costs And Expenses
CostsAndExpenses
317213000 usd
us-gaap Costs And Expenses
CostsAndExpenses
299050000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1965000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-61039000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
11176000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
11312000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
24828000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
27345000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
74067000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
83656000 usd
CY2023Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-737000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-37000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-665000 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29019000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60963000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-163067000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1123000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1741000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62086000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164808000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
170000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-67000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
786000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
841000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36039000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61130000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-164034000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
206466000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
206466000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189095000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189095000 shares
us-gaap Net Income Loss
NetIncomeLoss
-62086000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164808000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
937000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1232000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1361000 usd
us-gaap Inventory Write Down
InventoryWriteDown
236000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
44074000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
39127000 usd
bcrx Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs
NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts
53571000 usd
bcrx Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs
NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts
66286000 usd
bcrx Amortization Of Premium Discount On Investments
AmortizationOfPremiumDiscountOnInvestments
-8713000 usd
bcrx Amortization Of Premium Discount On Investments
AmortizationOfPremiumDiscountOnInvestments
-6814000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29019000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
15402000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
3125000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2001000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2357000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1385000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7530000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-59933000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-36678000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
449000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
227235000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
357419000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
262480000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
256008000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34796000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-103025000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4030000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8301000 usd
bcrx Proceeds From Issuance Of Common Stock Issued For Services
ProceedsFromIssuanceOfCommonStockIssuedForServices
29000 usd
bcrx Proceeds From Issuance Of Common Stock Issued For Services
ProceedsFromIssuanceOfCommonStockIssuedForServices
217000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4451000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
300000000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
240452000 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
0 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
21261000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
11147000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1348000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1740000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35658000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
368000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-160000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13383000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-153750000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112447000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99064000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
152489000 usd
us-gaap Interest Paid Net
InterestPaidNet
20242000 usd
us-gaap Interest Paid Net
InterestPaidNet
17151000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1225000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1444000 usd
bcrx Withholding Taxes Accrued
WithholdingTaxesAccrued
245000 usd
bcrx Withholding Taxes Accrued
WithholdingTaxesAccrued
2107000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-455528000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-566000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
38000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1129000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13652000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-476167000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12674000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-214000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
264000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13173000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-475606000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14033000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1736000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1362000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
723000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
6000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17249000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-294597000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53333000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
559000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3502000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1575000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14007000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-328287000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-75326000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
105000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1748000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
206000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12841000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-388713000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36149000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
110000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
456000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1020000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12279000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-410986000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s condensed consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
117085000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
319178000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
238011000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2223000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1804000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1410000 usd
bcrx Long Term Investment Maturity Minimum
LongTermInvestmentMaturityMinimum
P12M
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44441000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54772000 shares
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
117085000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
319178000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
238011000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
252598000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
278344000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
251146000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
588000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
864000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
252598000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
278131000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
135000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
150000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
72000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
278344000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
233172000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
278344000 usd
CY2024Q3 bcrx Maturing After One Year And Before Two Years
MaturingAfterOneYearAndBeforeTwoYears
19426000 usd
CY2023Q4 bcrx Maturing After One Year And Before Two Years
MaturingAfterOneYearAndBeforeTwoYears
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
252598000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
278344000 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1000000 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2296000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
7675000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6449000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
15757000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
17591000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8511000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6242000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
31943000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
30282000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2748000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1599000 usd
CY2024Q3 bcrx Inventory Including Noncurrent Portion
InventoryIncludingNoncurrentPortion
29195000 usd
CY2023Q4 bcrx Inventory Including Noncurrent Portion
InventoryIncludingNoncurrentPortion
28683000 usd
CY2023Q4 bcrx Royalty Financing Liabilities
RoyaltyFinancingLiabilities
531599000 usd
CY2024Q1 bcrx Non Cash Interest Expense On Royalty Financing Liabilities
NonCashInterestExpenseOnRoyaltyFinancingLiabilities
14187000 usd
CY2024Q1 bcrx Royalty Revenues Paid And Payable
RoyaltyRevenuesPaidAndPayable
-15212000 usd
CY2024Q1 bcrx Royalty Financing Liabilities
RoyaltyFinancingLiabilities
530574000 usd
CY2024Q2 bcrx Non Cash Interest Expense On Royalty Financing Liabilities
NonCashInterestExpenseOnRoyaltyFinancingLiabilities
14263000 usd
CY2024Q2 bcrx Royalty Revenues Paid And Payable
RoyaltyRevenuesPaidAndPayable
-21204000 usd
CY2024Q2 bcrx Royalty Financing Liabilities
RoyaltyFinancingLiabilities
523633000 usd
CY2024Q3 bcrx Non Cash Interest Expense On Royalty Financing Liabilities
NonCashInterestExpenseOnRoyaltyFinancingLiabilities
14019000 usd
CY2024Q3 bcrx Royalty Revenues Paid And Payable
RoyaltyRevenuesPaidAndPayable
-22877000 usd
CY2024Q3 bcrx Royalty Financing Liabilities
RoyaltyFinancingLiabilities
514775000 usd
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
569000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
666000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1741000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1559000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
455000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
300000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1278000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
823000 usd
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
81000 usd
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
48000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
231000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
123000 usd
CY2024Q3 bcrx Financing Lease Expense
FinancingLeaseExpense
536000 usd
CY2023Q3 bcrx Financing Lease Expense
FinancingLeaseExpense
348000 usd
bcrx Financing Lease Expense
FinancingLeaseExpense
1509000 usd
bcrx Financing Lease Expense
FinancingLeaseExpense
946000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1091
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1088
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0818
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0746
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8337000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8682000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1049000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1058000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8065000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8390000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9114000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9448000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3873000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
4322000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1839000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1590000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2077000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2845000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
3916000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
4435000 usd
CY2024Q3 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
5781000 usd
CY2023Q4 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
4794000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
3571000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
2293000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
412000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
410000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1920000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1985000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1684000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1152000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1594000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
678000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1416000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
147000 usd
CY2024Q3 bcrx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
7997000 usd
CY2024Q3 bcrx Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
0 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15023000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
4372000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5909000 usd
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
456000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9114000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
3916000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
231000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
908000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1731000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1376000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1348000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
261000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4462000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
828000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
686000 usd
bcrx Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities
NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities
365000 usd
bcrx Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities
NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities
629000 usd
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
63666000 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
58020000 shares
CY2024Q3 bcrx Share Based Payment Arrangement Number Of Plans
ShareBasedPaymentArrangementNumberOfPlans
3 plan
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17249000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12279000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44074000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39127000 usd
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
412000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
338000 shares
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
3380000 usd
CY2024Q1 us-gaap Restructuring Costs
RestructuringCosts
1264000 usd
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
3168000 usd
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
1476000 usd
CY2024Q2 us-gaap Restructuring Costs
RestructuringCosts
0 usd
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
1179000 usd
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
297000 usd
CY2024Q3 us-gaap Restructuring Costs
RestructuringCosts
0 usd
CY2024Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
291000 usd
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
6000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-045364-index-headers.html Edgar Link pending
0001628280-24-045364-index.html Edgar Link pending
0001628280-24-045364.txt Edgar Link pending
0001628280-24-045364-xbrl.zip Edgar Link pending
bcrx-20240930.htm Edgar Link pending
bcrx-20240930.xsd Edgar Link pending
bcrx-20240930xexx311.htm Edgar Link pending
bcrx-20240930xexx312.htm Edgar Link pending
bcrx-20240930xexx321.htm Edgar Link pending
bcrx-20240930xexx322.htm Edgar Link pending
biocrystpharmaceuticalsinc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
bcrx-20240930_cal.xml Edgar Link unprocessable
bcrx-20240930_def.xml Edgar Link unprocessable
bcrx-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcrx-20240930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcrx-20240930_pre.xml Edgar Link unprocessable